CY1117478T1 - Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα - Google Patents

Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα

Info

Publication number
CY1117478T1
CY1117478T1 CY20161100242T CY161100242T CY1117478T1 CY 1117478 T1 CY1117478 T1 CY 1117478T1 CY 20161100242 T CY20161100242 T CY 20161100242T CY 161100242 T CY161100242 T CY 161100242T CY 1117478 T1 CY1117478 T1 CY 1117478T1
Authority
CY
Cyprus
Prior art keywords
peptide
represented
integer
plasma
extend
Prior art date
Application number
CY20161100242T
Other languages
English (en)
Inventor
Naomi Wakabayashi
Seiji Sato
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of CY1117478T1 publication Critical patent/CY1117478T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/63Motilins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Πεπτίδιο του ακόλουθου (I) ή (II). (I) πεπτίδιο παριστώμενο από τον τύπο Β, Α-Β, B-C ή A-B-C στους οποίους οι Α, Β και C παρίσταται έκαστη από τα ακόλουθα (1), (2) και (3) και, όταν είναι ενωμένο σε άλλο πεπτίδιο-αντικείμενο, είναι ικανό να παρατείνει το χρόνο ημιζωής στο πλάσμα σε σύγκριση με το πεπτίδιο-αντικείμενο, με τη φυσιολογική δραστικότητα του πεπτιδίου-αντικειμένου να διατηρείται. (II) πεπτίδιο που περιλαμβάνει ανεστραμμένη αλληλουχία του πεπτιδίου του (I)· αλληλουχία η οποία παριστάται από Α-Β στο (I) και η Α ή Β είναι ανεστραμμένη· αλληλουχία η οποία παριστάται από B-C στο (I) και η Β ή C είναι ανεστραμμένη· ή αλληλουχία η οποία παριστάται από A-B-C στο (I) και οι Α, Β, C, Α και Β, και Β και C ή Α και C είναι διατηρημένη. (1) Η Α είναι πεπτίδιο που περιλαμβάνει 1 έως 14 οιωνδήποτε αμινοξέων (2) Η Β είναι πεπτίδιο που παρίσταται από τον τύπο 1: (Wk-X1-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s (Στον τύπο 1, η W είναι βασικό αμινοξύ· οι Χ και Ζ είναι οιαδήποτε αμινοξέα· η Υ είναι όξινο αμινοξύ· k είναι 1 ή 2· 1 είναι ακέραιος 4 ≥ 1 ≥ 0· m είναι ακέραιος 2 ≥ m ≥ 0· 4 ≥ 1 + m ≥ 0· n είναι 1 ή 2· ο είναι 1 ή 2· p είναι ακέραιος 4 ≥ p ≥ 0· q είναι ακέραιος 2 ≥ q ≥ 0· 4 ≥ p+q ≥ 0· r είναι 1 ή 2· και s είναι 0 ή 1). (3) Η C είναι πεπτίδιο που περιλαμβάνει 2 έως 14 οιωνδήποτε αμινοξέων.
CY20161100242T 2008-05-23 2016-03-22 Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα CY1117478T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008136106 2008-05-23
EP09750669.5A EP2277890B1 (en) 2008-05-23 2009-05-22 Peptide capable of extending half-life of peptide of interest in plasma

Publications (1)

Publication Number Publication Date
CY1117478T1 true CY1117478T1 (el) 2017-04-26

Family

ID=41340233

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100242T CY1117478T1 (el) 2008-05-23 2016-03-22 Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα

Country Status (16)

Country Link
US (1) US8551937B2 (el)
EP (1) EP2277890B1 (el)
JP (1) JP5524049B2 (el)
KR (2) KR20130018965A (el)
CN (1) CN101809029B (el)
BR (1) BRPI0904622A2 (el)
CA (1) CA2698582C (el)
CY (1) CY1117478T1 (el)
DK (1) DK2277890T3 (el)
ES (1) ES2566830T3 (el)
HR (1) HRP20160303T1 (el)
HU (1) HUE028539T2 (el)
PL (1) PL2277890T3 (el)
PT (1) PT2277890E (el)
SI (1) SI2277890T1 (el)
WO (1) WO2009142307A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235635B2 (en) 2004-04-21 2010-11-18 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
CA2758581C (en) 2009-05-20 2022-06-14 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
US20140072557A1 (en) 2011-02-28 2014-03-13 National Cerebral And Cardiovascular Center Medicinal agent for suppressing malignant tumor metastasis
KR20140054084A (ko) 2011-08-19 2014-05-08 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약
JPWO2013099376A1 (ja) * 2011-12-26 2015-04-30 国立大学法人福井大学 体外受精における成熟卵子マーカー及びその使用
TWI578995B (zh) * 2012-04-25 2017-04-21 第一三共股份有限公司 利尿鈉肽受體npr-b促效劑之用途
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
JPWO2015129812A1 (ja) * 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
PL3400019T3 (pl) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3452021B1 (en) * 2016-05-06 2021-12-29 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3574913A4 (en) 2017-01-24 2020-07-22 Daiichi Sankyo Company, Limited SMALL SIZE THERAPEUTIC AGENT
EP3601314A4 (en) * 2017-03-22 2021-01-13 Pharmain Corporation NPRA AGONISTS, COMPOSITIONS AND CORRESPONDING USES
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
JP7378839B2 (ja) * 2018-12-26 2023-11-14 スキンメドカンパニーリミテッド アセチルコリン受容体阻害ペプチド及びその用途
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトcnp遺伝子及び前駆体蛋白
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
US7385026B1 (en) 1999-07-23 2008-06-10 Kenji Kangawa Modified ghrelin polypeptides
EP1427750B1 (en) 2001-08-30 2010-12-08 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
ES2355488T3 (es) * 2001-08-30 2011-03-28 Biorexis Technology, Inc. Proteína de fusión de tranferrina modificadas.
US20090181888A1 (en) * 2005-11-21 2009-07-16 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
CA2630011A1 (en) * 2005-11-21 2007-05-24 University Of Miyazaki Skin repair accelerating therapeutic agent containing desacyl ghrelin and derivatives thereof as active ingredient
JPWO2008018597A1 (ja) * 2006-08-11 2010-01-07 国立大学法人 宮崎大学 デスアシルグレリン及びその誘導体を有効成分とする脊髄神経修復促進治療剤
RU2009108643A (ru) * 2006-08-11 2010-09-20 Юниверсити Оф Миязаки (Jp) Лекарственные средства, усиливающие репарацию спинномозговых нервов, содержащие в качестве активного ингредиента грелин или его производные или вещества, которые действуют на ghs-r1а
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks

Also Published As

Publication number Publication date
CA2698582A1 (en) 2009-11-26
KR101350251B1 (ko) 2014-01-14
JP5524049B2 (ja) 2014-06-18
EP2277890A4 (en) 2011-08-24
CN101809029B (zh) 2016-06-15
ES2566830T3 (es) 2016-04-15
EP2277890A1 (en) 2011-01-26
JPWO2009142307A1 (ja) 2011-09-29
PT2277890E (pt) 2016-03-31
BRPI0904622A2 (pt) 2016-06-21
CN101809029A (zh) 2010-08-18
SI2277890T1 (sl) 2016-04-29
KR20130018965A (ko) 2013-02-25
HRP20160303T1 (hr) 2016-04-22
KR20100038236A (ko) 2010-04-13
HUE028539T2 (en) 2016-12-28
US20100305031A1 (en) 2010-12-02
WO2009142307A1 (ja) 2009-11-26
EP2277890B1 (en) 2016-01-06
PL2277890T3 (pl) 2016-06-30
US8551937B2 (en) 2013-10-08
DK2277890T3 (en) 2016-02-08
CA2698582C (en) 2016-09-13

Similar Documents

Publication Publication Date Title
CY1117478T1 (el) Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα
CY1121658T1 (el) Πεπτιδια και χρηση αυτων
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
CY1123387T1 (el) Συνδυασμος δυο αντιιικων για τη θεραπεια της ηπατιτιδας c
CY1124146T1 (el) Συστηματα εκφρασης
CY1120407T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
CY1120426T1 (el) Πολυπεπτιδιο ace2
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
BR112013023911A2 (pt) amidas de ácido n-(1,3,4-oxadiazol-2-il)-arilcarboxílico e o uso das mesmas como herbicidas
TR201907397T4 (tr) Il-15 ve ıl-15 alfa suşi alanı bazlı immünositokinler.
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
DE602005008996D1 (de) Radiofluorierte peptide
CY1112182T1 (el) Μεθοδος για την αμιδιωση πολυπεπτιδιων με καρβοξυτελικα βασικα αμινοξεα με τη χρηση ειδικων ενδοπρωτεασων
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
CY1120424T1 (el) Πεπτιδια λαμβανομενα απο ανθρωπινη bplp πρωτεϊνη, πολυνουκλεοτιδια που κωδικοποιουν τα εν λογω πεπτιδια και αντισωματα κατευθυνομενα εναντι των εν λογω πεπτιδιων
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
ES2570458T3 (es) Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie